Human Pathology
Volume 41, Issue 4 , Pages 461-476, April 2010

8p11 myeloproliferative syndrome: a review

  • Courtney C. Jackson, MD

      Affiliations

    • Dr Jackson did this work, in part, when she was a fellow at Baylor College of Medicine. Her current address is Department of Pathology, The University of Mississippi Medical Center, Jackson.
  • ,
  • L. Jeffrey Medeiros, MD
  • ,
  • Roberto N. Miranda, MD

      Affiliations

    • Corresponding Author InformationCorresponding author.

Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

Received 25 August 2009; received in revised form 1 November 2009; accepted 4 November 2009.

Summary 

The 8p11 myeloproliferative syndrome is an aggressive neoplasm associated with chromosomal translocations involving the fibroblast growth factor receptor 1 tyrosine kinase gene on chromosome 8p11-12. By our count, 65 cases are currently reported in the literature. This neoplasm affects patients of all ages, with a slight male predominance. Patients often present with peripheral blood eosinophilia without basophilia. Bone marrow examination commonly is hypercellular, with or without eosinophilia, which usually leads to the initial diagnosis of a myeloproliferative neoplasm. Many patients also present with or develop lymphadenopathy. Lymph node biopsy in these patients has commonly shown lymphoblastic leukemia/lymphoma, most often reported as being of T-cell lineage, but bilineal myeloid/T-cell lymphomas and less often a myeloid sarcoma are also reported. The natural history of this neoplasm is to evolve into acute leukemia, usually of myeloid or mixed lineage, and less frequently of T- or B-lymphoid lineage. The prognosis is poor despite aggressive chemotherapy, with a few patients achieving long clinical remission after stem cell transplantation. At the molecular level, all cases carry a chromosomal abnormality involving the fibroblast growth factor receptor 1 (FGFR1) gene at chromosome 8p11, where 10 translocations and 1 insertion have been identified. These abnormalities disrupt the FGFR1 and various partner genes, and result in the creation of novel fusion genes and chimeric proteins. The latter include the N-terminal portion of the partner genes and the C-terminal portion of FGFR1. The most common partner is ZNF198 on chromosome 13q12. In the current World Health Organization classification, the 8p11 myeloproliferative syndrome is designated as “myeloid and lymphoid neoplasms with FGFR1 abnormalities.”

Keywords: 8p11 myeloproliferative syndrome, Stem cell leukemia/lymphoma syndrome, Myeloproliferative neoplasm, Fibroblast growth factor receptor 1 (FGFR1), t(8;13)(p11;q12), ZNF198

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0046-8177(09)00406-7

doi:10.1016/j.humpath.2009.11.003

Human Pathology
Volume 41, Issue 4 , Pages 461-476, April 2010